QuidelOrtho (QDEL) Net Income towards Common Stockholders (2021 - 2026)
QuidelOrtho (QDEL) reported Net Income towards Common Stockholders of $700000.0 for Q1 2026, up 118.92% on a YoY basis from $319753.1 in Q1 2025, and up 177.78% sequentially from -$900000.0 in Q4 2025.
QuidelOrtho (QDEL) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
QuidelOrtho (QDEL) has 6 years of Net Income towards Common Stockholders data on file, last reported at $700000.0 in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 118.92% year-over-year to $700000.0; the trailing twelve-month figure through Mar 2026 stood at -$6.7 million (up 67.32% YoY), and the FY2025 full-year result was -$11.1 million, up 99.46% from the prior year.
- Net Income towards Common Stockholders improved to $700000.0 in Q1 2026, from -$900000.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $479.9 million in Q2 2022 to a low of -$1.7 billion in Q1 2024.
- A 5-year average of -$97.0 million and a median of -$3.6 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders plunged 3607.99% in 2024 and soared 118.92% in 2026, its largest moves.
- Tracing QDEL's Net Income towards Common Stockholders over 5 years: stood at $19.2 million in 2022, then tumbled by 2892.19% to -$536.1 million in 2023, then jumped by 99.29% to -$3.8 million in 2024, then jumped by 76.32% to -$900000.0 in 2025, then jumped by 177.78% to $700000.0 in 2026.
- Business Quant data shows QDEL's Net Income towards Common Stockholders at $700000.0 in Q1 2026, -$900000.0 in Q4 2025, and -$2.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | QuidelOrtho | 1.15 Bn | 1.01 Bn | - | 700,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 700,000.00 |
| Dec 28, 2025 | -900,000.00 |
| Sep 28, 2025 | -2.90 Mn |
| Jun 29, 2025 | -3.60 Mn |
| Mar 30, 2025 | -3.70 Mn |
| Dec 29, 2024 | -3.80 Mn |
| Sep 29, 2024 | -6.80 Mn |
| Jun 30, 2024 | -6.20 Mn |
| Mar 31, 2024 | -1.71 Bn |
| Dec 31, 2023 | -536.10 Mn |
| Oct 1, 2023 | -19.00 Mn |
| Jul 2, 2023 | -57.50 Mn |
| Apr 2, 2023 | 48.80 Mn |
| Jan 1, 2023 | 135.80 Mn |
| Oct 2, 2022 | 19.20 Mn |
| Jul 3, 2022 | 19.30 Mn |
| Apr 3, 2022 | 479.90 Mn |
| Oct 3, 2021 | 215.70 Mn |
| Jul 4, 2021 | 19.10 Mn |